Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Equities researchers at Zacks Research lifted their Q1 2026 earnings per share (EPS) estimates for shares of Corcept ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Corcept Therapeutics (NASDAQ:CORT – Free Report) had its target price lifted by Piper Sandler from $128.00 to $131.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

Corcept Therapeutics Incorporated’s CORT share price has surged by 82.59%, which has investors questioning if this is right ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Corcept Therapeutics CORT over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below ...